Catherine M. Sherwin, BSc (Hons), PhD, BN, MSCI

Division Chief of Pediatric Clinical Pharmacology

Research Interests

  • Clinical Pediatric Pharmacology and Toxicology
  • Pharmacokinetics
  • Pharmacodynamics
  • Pharmacogenomics
  • Modeling and Simulation (Pharmacometrics)
  • Clinical Trial Simulation
  • Optimal Trial Design
  • Therapeutics
  • Toxicology
  • Personalized Medicine

Languages

  • English

Academic Information

  • Departments: Pediatrics - Associate Professor, Pharmaceutics and Pharmaceutical Chemistry - Adjunct Associate Professor, Pharmacology and Toxicology - Adjunct Assistant Professor, Pharmacotherapy - Adjunct Associate Professor
  • Divisions: Pediatric Clinical Pharmacology

Board Certification

  • American Board of Clinical Pharmacology

Academic Office Information

  • 801-587-7404
  • Williams Building
    295 Chipeta Way
    Salt Lake City, UT 84108

Research Statement

Dr. Catherine Sherwin is currently an Associate Professor and Chief of the Division of Clinical Pharmacology, Department of Pediatrics, University of Utah School of Medicine. She earned her PhD at the University of Otago, Dunedin School of Medicine, New Zealand in Paediatric Clinical Pharmacology in 2007. She then completed one year of Postdoctoral training in the Women’s and Children’s Health in Dunedin and then a two year T32 Fellowship training program in the Divisions of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center. She received board certification from the American Board of Clinical Pharmacology in 2011. Dr. Sherwin has expertise and experience in the development of quantitative pharmacometric (PK/PD/PG) models in special populations including pediatric and neonatal patients.

Dr. Sherwin’s areas of clinical research focus are clinical pharmacology/toxicology and pharmacometrics within the area of pediatrics and maternal health, and specifically the juncture of the two: neonatology and pregnancy. She is highly committed to understanding how physical size and physiological based information can be systematically utilized understand the inherent pharmacology. She has a combination of skill sets that are in high demand; having been trained in pediatric clinical pharmacology and pharmacometrics. The natural overlap between these two areas of expertise complement one another and allow Dr. Sherwin to provide a unique level of technical depth and research insight to pediatric studies. Dr. Sherwin’s research has a highly clinical focus and combines the utility and innovation of modeling and simulation to provide research answers to real clinical questions.

Academic Bio

Dr. Catherine Sherwin completed her PhD in Clinical Pharmacology in the Department of Pediatrics and Women’s Health at the University of Otago, Dunedin, New Zealand. Her Postdoctoral training includes a Fellowship in Pediatrics and Child Health at the University of Otago and a Postdoctoral Research Fellowship undertaken in the Divisions of Pediatric Rheumatology and Pharmacology at Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio. She is currently an Associate Professor at the University of Utah. Dr. Sherwin is the Chief of the Divsion of Clinical Pharmacology and leads the research team within the Division and also has a role in the Clinical Trials Office within the Department of Pediatrics.

Dr. Sherwin’s research and expertise is in pharmacokinetic, pharmacodynamic and pharmacogenomic modeling as well as clinical trial simulation. Her research involves understanding the pharmacology of drugs in neonatal and pediatric populations which has allowed her to become an expert in the techniques of pharmacometric modeling and scaling which are crucial for pediatric clinical trials. Dr. Sherwin has specific interests and expertise with numerous drug classes including antibiotics, immunosuppressants, antiepileptics, anesthetic agents and opioids.

Education History

Type School Degree
Graduate Training University of Utah
Clinical Investigation
M.Sc.
Postdoctoral Fellowship Cincinnati Children's Hospital Medical Center, Division of Clinical Pharmacology
Pediatric Clinical Pharmacology
Postdoctoral Fellow
Postdoctoral Fellowship University of Otago, Department of Women’s and Children’s Health
Pediatric Clinical Pharmacology
Postdoctoral Fellow
Doctoral Training University of Otago, Dunedin School of Medicine
Pediatric Clinical Pharmacology
Ph.D.
Other Training Otago School of Medicine and Health Sciences, Department Pharmacology & Toxicology
Summer Studentship - Toxicology
Other Training Christchurch School of Medicine and Health Sciences, Canterbury Health Laboratory
Summer Studentship - Toxicology
Undergraduate Lincoln University
Toxicology and Immunology
B.Sc. (Hons)
Undergraduate Australian Catholic University
Nursing
B.N.
Certification Meadowbank TAFE College, Concord General Repatriation Hospital
Adv. Certificate Enrolled Nursing
Certificate

Global Impact

Education History

Type School Degree Country
Postdoctoral Fellowship University of Otago, Department of Women’s and Children’s Health
Pediatric Clinical Pharmacology
Postdoctoral Fellow New Zealand
Doctoral Training University of Otago, Dunedin School of Medicine
Pediatric Clinical Pharmacology
Ph.D. New Zealand
Other Training Otago School of Medicine and Health Sciences, Department Pharmacology & Toxicology
Summer Studentship - Toxicology
New Zealand
Other Training Christchurch School of Medicine and Health Sciences, Canterbury Health Laboratory
Summer Studentship - Toxicology
New Zealand
Undergraduate Lincoln University
Toxicology and Immunology
B.Sc. (Hons) New Zealand
Undergraduate Australian Catholic University
Nursing
B.N. Australia
Certification Meadowbank TAFE College, Concord General Repatriation Hospital
Adv. Certificate Enrolled Nursing
Certificate Australia

Awards & Honors

Description Country
Manuscript recognised as most accessed article from BMC Pharmacology and Toxicology. Yu T, Balch AH, Ward RM, Korgenski EK, Sherwin CM (2016). Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates. BMC Pharmacol Toxicol, 17(1), 22. United Kingdom
Editors' Performance Prize British Journal of Clinical Pharmacology 2016 United Kingdom

Grand Rounds

Description Country
Clinical Pharmacology: Solving your Clinical Headaches, Erasmus MC-Sophia, University Medical Center, Rotterdam, The Netherlands, Oct 2015 Netherlands

Presentations

Description Country
Neonatal Sepsis, Applying Regulatory Science to Neonates: Launch of the International Neonatal Consortium (INC), Co-Organized by the Critical Path Institute and the European Medicines Agency, May 18 2015, London, UK United Kingdom
Paediatric Clinical Pharmacology meeting at the UCL Institute of Child Health, 2015, Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George’s, University of London, UK United Kingdom

Career

Institution Description Country
Kogarah Veterinary Clinic Veterinary Nurse Australia
Concord General Repatriation Hospital Nurse Training Program Australia
St George Public Hospital, Cardiothoracic Unit Nurse Australia
St George Private Hospital, Cardiothoracic Unit Nurse Australia
Christchurch Hospital Phlebotomy Technician New Zealand
Southern Cross Private Hospital, Cardiothoracic Unit Nurse New Zealand
After Hours Veterinary Centre Senior Veterinary Nurse New Zealand
Dunedin Public Hospital Phlebotomy Technician New Zealand
University of Otago, Dunedin School of Medicine Teaching Fellow New Zealand
University of Otago, Dept. Pharmacology and Toxicology Case Tutor for Pharm/Tox students and Pharmacy students New Zealand
University of Otago, Dunedin School of Medicine Case Tutor (2nd year Medicine), Faculty of Medicine New Zealand
University of Otago, Dept. of Women’s and Children’s Health, School of Medicine Masonic Research Postdoctoral Fellow New Zealand
University of Otago, Department of Pharmacology and Toxicology Demonstrator / Tutor New Zealand
University of Otago Tutor for microbiology/immunology and physiology, Faculty of Medicine and Department of Microbiology and Immunology New Zealand
University of Otago, School of Medicine Tutor for microbiology/immunology, physiology, zoology and pre-health science, Pacific Island Centre and Maori Centre New Zealand
University of Otago, Department of Microbiology, Immunology, Physiology and Department of Zoology Senior laboratory demonstrator / Leader New Zealand

Selected Publications

Journal Article

  1. Constance JE, Campbell SC, Somani AA, Yellepeddi V, Owens KH, Sherwin CM (6/1/2017). Pharmacokinetics, Pharmacodynamics and Pharmacogenetics associated with Nonsteroidal Anti-Inflammatory Drugs and Opioids in Pediatric Cancer Patients. Expert Opinion on Drug Metabolism and Toxicology, (Jun 5), 1-10.
  2. Rower JE, Liu X, Yu T, Mundorff M, Sherwin CM, Johnson MD (2017). Clinical pharmacokinetics of magnesium sulfate in the treatment of children with severe acute asthma. Eur J Clin Pharmacol, 73(3), 325-331.
  3. Enioutina EY, Salis ER, Job KM, Gubarev MI, Krepkova LV, Sherwin CM (2017). Herbal Medicines: challenges in the modern world. Part 5. status and current directions of complementary and alternative herbal medicine worldwide. Expert Rev Clin Pharmacol, 10(3), 327-338.
  4. Lanke S, Yu T, Rower JE, Balch AH, Korgenski EK, Sherwin CM (2017). AUC-Guided Vancomycin Dosing in Adolescent Patients With Suspected Sepsis. J Clin Pharmacol, 57(1), 77-84.
  5. Job KM, Kiang TK, Constance JE, Sherwin CM, Enioutina EY (2016). Herbal medicines: challenges in the modern world. Part 4. Canada and United States. Expert Rev Clin Pharmacol, 9(12), 1597-1609.
  6. Jones BL, Sherwin CM, Liu X, Dai H, Vyhlidal CA (2016). Genetic Variation in the Histamine Production, Response, and Degradation Pathway Is Associated with Histamine Pharmacodynamic Response in Children with Asthma. Front Pharmacol, 7, 524.
  7. Janssen EJ, Valitalo PA, Allegaert K, de Cock RF, Simons SH, Sherwin CM, Mouton J, van den Anker JN, Knibbe CA (2016). Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. Antimicrob Agents Chemother, 60(2), 1031-21.
  8. Campbell SC, Kast TT, Kamyar M, Robertson J, Sherwin CM (2016). Calls to a teratogen information service regarding potential exposures in pregnancy and breastfeeding. BMC Pharmacol Toxicol, 17(1), 33.
  9. Job KM, Olson J, Stockmann C, Constance JE, Enioutina EY, Rower JE, Linakis MW, Balch AH, Yu T, Liu X, Thorell EA, Sherwin CM (2016). Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections. Expert Rev Anti Infect Ther, 14(8), 731-46.
  10. Tak CR, Yu T, Sherwin CM, Mihalopoulos NL (2016). Optimizing enrollment in pediatric obese patients: reflections on recruitment characteristics.LID - 10.1515/ijamh-2016-0029 [doi]LID - /j/ijamh.ahead-of-print/ijamh-2016-0029/ijamh-2016-0029.xml [pii]. (Epub ahead of print) Int J Adolesc Med Health.
  11. Yu T, Balch AH, Ward RM, Korgenski EK, Sherwin CM (2016). Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates. BMC Pharmacol Toxicol, 17(1), 22.
  12. Liu X, Jones BL, Roberts JK, Sherwin CM (2016). Population pharmacokinetic/pharmacodynamic modeling of histamine response measured by histamine iontophoresis laser Doppler. J Pharmacokinet Pharmacodyn, 43(4), 385-93.
  13. Dobson NR, Liu X, Rhein LM, Darnall RA, Corwin MJ, McEntire BL, Ward RM, James LP, Sherwin CM, Heeren TC, Hunt CE (2016). Salivary caffeine concentrations are comparable to plasma concentrations in preterm infants receiving extended caffeine therapy. Br J Clin Pharmacol, 82(3), 754-61.
  14. Sammons HM, Gubarev MI, Krepkova LV, Bortnikova VV, Corrick F, Job KM, Sherwin CM, Enioutina EY (2016). Herbal medicines: challenges in the modern world. Part 2. European Union and Russia. Expert Rev Clin Pharmacol, 9(8), 1117-27.
  15. Stockmann C, Sammons H, Starkey E, Constance JE, Sherwin CM (2016). Unanswered Questions Regarding Optimal Pediatric Vancomycin Use. Ther Drug Monit, 38(3), 419-20.
  16. Cook SF, Stockmann C, Samiee-Zafarghandy S, King AD, Deutsch N, Williams EF, Wilkins DG, Sherwin CM, van den Anker JN (2016). Neonatal Maturation of Paracetamol (Acetaminophen) Glucuronidation, Sulfation, and Oxidation Based on a Parent-Metabolite Population Pharmacokinetic Model. Clin Pharmacokinet, 55(11), 1395-1411.
  17. Teng L, Zu Q, Li G, Yu T, Job KM, Yang X, Di L, Sherwin CM, Enioutina EY (2016). Herbal medicines: challenges in the modern world. Part 3. China and Japan. Expert Rev Clin Pharmacol, 9(9), 1225-33.
  18. Burch PT, Spigarelli MG, Lambert LM, Loftus PD, Sherwin CM, Linakis MW, Sheng X, LuAnn Minich L, Williams RV (2016). Use of Oxandrolone to Promote Growth in Neonates following Surgery for Complex Congenital Heart Disease: An Open-Label Pilot Trial. Congenit Heart Dis, 11(6), 693-699.
  19. Stockmann C, Sammons H, Starkey E, Constance JE, Sherwin CM (2016). Unanswered questions regarding optimal pediatric vancomycin use. Ther Drug Monit, Apr 14.
  20. Barnes J, McLachlan AJ, Sherwin CM, Enioutina EY (2016). Herbal medicines: challenges in the modern world. Part 1. Australia and New Zealand. Expert Rev Clin Pharmacol, 9(7), 905-15.
  21. Janssen EJ, Valitalo PA, Allegaert K, de Cock RF, Simons SH, Sherwin CM, Mouton JW, van den Anker JN, Knibbe CA (2016). Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. Antimicrob Agents Chemother, 60(2), 1013-21.
  22. Bhongsatiern J, Stockmann C, Yu T, Constance JE, Moorthy G, Spigarelli MG, Desai PB, Sherwin CM (2016). Renal Function Descriptors in Neonates: Which Creatinine-Based Formula Best Describes Vancomycin Clearance? J Clin Pharmacol, 56(5), 528-40.
  23. Yu T, Campbell SC, Stockmann C, Tak C, Schoen K, Clark EA, Varner MW, Spigarelli MG, Sherwin CM (2016). Pregnancy-induced changes in the pharmacokinetics of caffeine and its metabolites. J Clin Pharmacol, 56(5), 590-6.
  24. Cook SF, Roberts JK, Samiee-Zafarghandy S, Stockmann C, King AD, Deutsch N, Williams EF, Allegaert K, Wilkins DG, Sherwin CM, van den Anker JN (2016). Population Pharmacokinetics of Intravenous Paracetamol (Acetaminophen) in Preterm and Term Neonates: Model Development and External Evaluation. Clin Pharmacokinet, 55(1), 107-19.
  25. Linakis MW, Roberts JK, Lala AC, Spigarelli MG, Medlicott NJ, Reith DM, Ward RM, Sherwin CM (2016). Challenges Associated with Route of Administration in Neonatal Drug Delivery. Clin Pharmacokinet, 55(2), 185-96.
  26. Constance JE, Balch AH, Stockmann C, Linakis MW, Korgenski EK, Roberts JK, Ward RM, Sherwin CM, Spigarelli MG (2015). A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates. Arch Dis Child Fetal Neonatal Ed, Sep 23.
  27. Baserga MC, Beachy JC, Roberts JK, Ward RM, DiGeronimo RJ, Walsh WF, Ohls RK, Anderson J, Mayock DE, Juul SE, Christensen RD, Loertscher MC, Stockmann C, Sherwin CM, Spigarelli MG, Yoder BA (2015). Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. Pediatr Res, 78(3), 315-22.
  28. Bhongsatiern J, Stockmann C, Roberts JK, Yu T, Korgenski KE, Spigarelli MG, Desai PB, Sherwin CM (2015). Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration >/=400 Target. Ther Drug Monit, 37(6), 756-65.
  29. Grimsrud KN, Sherwin CM, Constance JE, Tak C, Zuppa AF, Spigarelli MG, Mihalopoulos NL (2015). Special population considerations and regulatory affairs for clinical research. Clin Res Regul Aff, 32(2), 47-56.
  30. Enioutina EY, Constance JE, Stockmann C, Linakis MW, Yu T, Rower JE, Balch AH, Sherwin CM (2015). Pharmacokinetic considerations in the use of antivirals in neonates. Expert Opin Drug Metab Toxicol, 11(12), 1861-78.
  31. Roberts JK, Cook SF, Stockmann C, Rollins DE, Wilkins DG, Sherwin CM (2015). A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults. Clin Drug Investig, 35(10), 633-43.
  32. Yang X, Sherwin CM, Yu T, Yellepeddi VK, Brunner HI, Vinks AA (2015). Pharmacokinetic modeling of therapies for systemic lupus erythematosus. Expert Rev Clin Pharmacol, 8(5), 587-603.
  33. Roberts JK, Stockmann C, Ward RM, Beachy J, Baserga MC, Spigarelli MG, Sherwin CM (2015). Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy. Clin Pharmacokinet, 54(12), 1237-44.
  34. Stockmann C, Hersh AL, Roberts JK, Bhongsatiern J, Korgenski EK, Spigarelli MG, Sherwin CM, Frymoyer A (2015). Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates. Infect Dis Ther, 4(2), 187-98.
  35. Linakis MW, Stockmann C, Campbell SC, Williams RV, Burch PT, Lambert LM, Sherwin CM, Reilly CA, Spigarelli MG (2015). Quantitative Assay Validation for Oxandrolone in Human Plasma Using LC-MS-MS. J Anal Toxicol, 39(7), 526-31.
  36. Stockmann C, Barrett JS, Roberts JK, Sherwin CM (2015). Use of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing Regimens. CPT Pharmacometrics Syst Pharmacol, 4(11), 630-40.
  37. Stockmann C, Ampofo K, Pavia AT, Byington CL, Blaschke AJ, Sherwin CM, Spigarelli MG, Hersh AL (2015). National trends in the incidence, outcomes and charges of pediatric osteoarticular infections, 1997-2012. Pediatr Infect Dis J, 34(6), 672-4.
  38. Stockmann C, Reilly CA, Fassl B, Gaedigk R, Nkoy F, Stone B, Roberts JK, Uchida DA, Leeder JS, Sherwin CM, Spigarelli MG, Yost GS, Ward RM (2015). Effect of CYP3A5*3 on asthma control among children treated with inhaled beclomethasone. J Allergy Clin Immunol, 136(2), 505-7.
  39. Stockmann C, Roberts JK, Yellepeddi VK, Sherwin CM (2015). Clinical pharmacokinetics of inhaled antimicrobials. Clin Pharmacokinet, 54(5), 473-92.
  40. Stockmann C, Spigarelli MG, Healy D, Gottschlich M, Kagan R, Balch AH, Sherwin CM (2015). Application of a method used to deconstruct a single dose pharmacokinetic profile from multiple dose data. Biopharm Drug Dispos, 12(Epub).
  41. Roberts JK, Stockmann C, Balch A, Yu T, Ward RM, Spigarelli MG, Sherwin CM (2015). Optimal design in pediatric pharmacokinetic and pharmacodynamic clinical studies. Paediatr Anaesth, 25(3), 222-30.
  42. Stockmann C, Roberts JK, Knackstedt ED, Spigarelli MG, Sherwin CM (2015). Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection. Expert Opin Drug Metab Toxicol, 11(2), 205-19.
  43. Stockmann C, Hillyard B, Ampofo K, Spigarelli MG, Sherwin CM (2015). Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis. Expert Rev Respir Med, 9(1), 13-22.
  44. Balch AH, Constance JE, Thorell EA, Stockmann C, Korgenski EK, Campbell SC, Spigarelli MG, Sherwin CM (2015). Pediatric vancomycin dosing: Trends over time and the impact of therapeutic drug monitoring. J Clin Pharmacol, 55(2), 212-20.
  45. Ward RM, Sherwin CM (2015). Ethics of drug studies in the newborn. Paediatr Drugs, 17(1), 37-42.
  46. Yu T, Stockmann C, Healy DP, Olson J, Wead S, Neely AN, Kagan RJ, Spigarelli MG, Sherwin CM (2015). Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis. J Burn Care Res, 36(4), e244-52.
  47. Stockmann C, Gottschlich MM, Healy D, Khoury JC, Mayes T, Sherwin CM, Spigarelli MG, Kagan RJ (2015). Relationship between zolpidem concentrations and sleep parameters in pediatric burn patients. J Burn Care Res, 36(1), 137-44.
  48. Sherwin CM, Stockmann C, Grimsrud K, Herd DW, Anderson BJ, Spigarelli MG (2015). Development of an optimal sampling schedule for children receiving ketamine for short-term procedural sedation and analgesia. Paediatr Anaesth, 25(2), 211-6.
  49. Doll E, Wilkes J, Cook LJ, Korgenski EK, Faix RG, Yoder BA, Srivastava R, Sherwin CM, Spigarelli MG, Clark EA, Bonkowsky JL (2014). Neonatal magnesium levels correlate with motor outcomes in premature infants: a long-term retrospective cohort study. Front Pediatr, 2, 120.
  50. Lala AC, Broadbent RS, Medlicott NJ, Sherwin CM, Reith DM (2014). Illustrative neonatal cases regarding drug delivery issues. J Paediatr Child Health.
  51. Yakub SY, Constance JE, Stockmann C, Linakis M, Campbell SC, Sherwin CM, Korgenski EK, Balch A, Spigarelli MG (2014). Epidemiological Evaluation of Blood Culture among Neonates Receiving Vancomycin. Indian J Microbiol, 54(4), 389-395.
  52. Stockmann C, Roberts JK, Yu T, Constance JE, Knibbe CA, Spigarelli MG, Sherwin CM (2014). Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections. Expert Rev Anti Infect Ther, 12(11), 1371-1388.
  53. De Cock RF, Allegaert K, Brussee JM, Sherwin CM, Mulla H, de Hoog M, van den Anker JN, Danhof M, Knibbe CA (2014). Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharm Res, 31(10), 2643-54.
  54. Roberts JK, Stockmann C, Constance JE, Stiers J, Spigarelli MG, Ward RM, Sherwin CM (2014). Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants. Clin Pharmacokinet, 53(7), 581-610.
  55. Sherwin CM, Ngamprasertwong P, Sadhasivam S, Vinks AA (2014). Utilization of optimal study design for maternal and fetal sheep propofol pharmacokinetics study: a preliminary study. Curr Clin Pharmacol, 9(1), 64-9.
  56. De Cock RF, Allegaert K, Sherwin CM, Nielsen EI, de Hoog M, van den Anker JN, Danhof M, Knibbe CA (2014). A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res, 31(3), 754-67.
  57. Sherwin CM, Balch A, Campbell SC, Fredrickson J, Clark EA, Varner M, Stockmann C, Korgenski EK, Bonkowsky JL, Spigarelli MG (2014). Maternal magnesium sulphate exposure predicts neonatal magnesium blood concentrations. Basic Clin Pharmacol Toxicol, 114(4), 318-22.
  58. Stockmann C, Sherwin CM, Koren G, Campbell SC, Constance JE, Linakis M, Balch A, Varner MW, Spigarelli MG (2014). Characteristics and publication patterns of obstetric studies registered in ClinicalTrials.gov. J Clin Pharmacol, 54(4), 432-7.
  59. Yu T, Stockmann C, Balch AH, Spigarelli MG, Sherwin CM (2014). Evolution of interventional vancomycin trials in light of new antibiotic development in the USA, 1999-2012. Int J Antimicrob Agents, 43(3), 215-22.
  60. Stockmann C, Spigarelli MG, Campbell SC, Constance JE, Courter JD, Thorell EA, Olson J, Sherwin CM (2014). Considerations in the pharmacologic treatment and prevention of neonatal sepsis. Paediatr Drugs, 16(1), 67-81.
  61. Lacher SE, Gremaud JN, Skagen K, Steed E, Dalton R, Sugden KD, Cardozo-Pelaez F, Sherwin CM, Woodahl EL (2014). Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat. J Pharmacol Exp Ther, 348(2), 336-45.
  62. Stockmann C, Sherwin CM, Ampofo K, Spigarelli MG (2014). Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis. Ther Adv Respir Dis, 8(1), 13-21.
  63. Stockmann C, Sherwin CM, Buterbaugh W, Spigarelli MG, Gottschlich MM, Healy D, Kagan RJ (2014). Preliminary assessment of zolpidem pharmacokinetics in pediatric burn patients. Ther Drug Monit, 36(3), 295-301.
  64. Sherwin CM, Zobell JT, Stockmann C, McCrory BE, Wisdom M, Young DC, Olson J, Ampofo K, Spigarelli MG (2014). Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis. J Pharmacokinet Pharmacodyn, 41(1), 71-9.
  65. Stockmann C, Hersh AL, Sherwin CM, Spigarelli MG (2014). Alignment of United States funding for cardiovascular disease research with deaths, years of life lost, and hospitalizations. Int J Cardiol, 172(1), e19-21.
  66. Sherwin CM, Medlicott NJ, Reith DM, Broadbent RS (2014). Intravenous drug delivery in neonates: lessons learnt. Arch Dis Child, 99(6), 590-4.
  67. Campbell SC, Stockmann C, Balch A, Clark EA, Kamyar M, Varner M, Korgenski EK, Bonkowsky JL, Spigarelli MG, Sherwin CM (2014). Intrapartum magnesium sulfate and the potential for cardiopulmonary drug-drug interactions. Ther Drug Monit, 36(4), 544-8.
  68. Sherwin CM, Wead S, Stockmann C, Healy D, Spigarelli MG, Neely A, Kagan R (2014). Amikacin population pharmacokinetics among paediatric burn patients. Burns, 40(2), 311-8.
  69. Stockmann C, Spigarelli MG, Ampofo K, Sherwin CM (2013). Bioequivalence and Bioavailability Clinical Trials: A Status Report from the National Institutes of Health ClinicalTrials.gov Registry. J Bioequiv Availab, 5, 244-247.
  70. Young DC, Zobell JT, Stockmann C, Waters CD, Ampofo K, Sherwin CM, Spigarelli MG (2013). Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. Pediatr Pulmonol, 48(11), 1047-61.
  71. Jones BL, Kearns G, Neville KA, Sherwin CM, Spigarelli MM, Leeder JS (2013). Variability of histamine pharmacodynamic response in children with allergic rhinitis. J Clin Pharmacol, 53(7), 731-7.
  72. Stockmann C, Sherwin CM, Ampofo K, Hersh AL, Pavia AT, Byington CL, Ward RM, Spigarelli MG (2013). Characteristics of antimicrobial studies registered in the USA through ClinicalTrials.Gov. Int J Antimicrob Agents, 42(2), 161-6.
  73. Stockmann C, Sherwin CM, Zobell JT, Lubsch L, Young DC, Olson J, Noyes BE, Ampofo K, Spigarelli MG (2013). Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis. Pharmacotherapy, 33(12), 1288-96.
  74. Zobell JT, Young DC, Waters D, Stockmann C, Ampofo K, Sherwin CM, Spigarelli MG (2013). Optimization of Anti-pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: II. Cephalosporins and Penicillins. Pediatr Pulmonol, 48(2), 107-22.
  75. Stockmann C, Sherwin CM, Zobell JT, Young DC, Waters CD, Spigarelli MG, Ampofo K (2013). Optimization of Anti-pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: III. Fluoroquinolones. Pediatr Pulmonol, 48(3), 211-20.
  76. Young DC, Zobell JT, Waters CD, Ampofo K, Stockmann C, Sherwin CM, Spigarelli MG (2013). Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. Colistimethate sodium. Pediatr Pulmonol, 48(1), 1-7.
  77. Zobell JT, Young DC, Waters CD, Ampofo K, Stockmann C, Sherwin CM, Spigarelli MG (2013). Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary. Pediatr Pulmonol, 48(6), 525-37.
  78. Zobell JT, Waters D, Young DC, Stockmann C, Ampofo K, Sherwin CM, Spigarelli MG (2012). Optimization of Anti-pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: I. Aztreonam and Carbapenems. Pediatr Pulmonol, 47(12), 1147-58.
  79. Sherwin CM, Saldana SN, Bies RR, Aman MG, Vinks AA (2012). Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents. Ther Drug Monit, 34(5), 535-44.
  80. Sherwin CM, Sagcal-Gironella AC, Fukuda T, Brunner HI, Vinks AA (2012). Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. Br J Clin Pharmacol, 73(5), 727-40.
  81. De Cock RF, Allegaert K, Schreuder MF, Sherwin CM, de Hoog M, van den Anker JN, Danhof M, Knibbe CA (2012). Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet, 51(2), 105-17.
  82. Sagcal-Gironella AC, Fukuda T, Wiers K, Cox S, Nelson S, Dina B, Sherwin CM, Klein-Gitelman MS, Vinks AA, Brunner HI (2011). Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum, 40, 307-313.
  83. Sherwin CM, Ding L, Kaplan J, Spigarelli MG, Vinks AA (2011). Optimal study design for pioglitazone in septic pediatric patients. J Pharmacokinet Pharmacodyn, 38, 433-447.
  84. Sagcal-Gironella AC, Sherwin CM, Tirona RG, Rieder MJ, Brunner HI, Vinks AA (2011). Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. Clin Ther, 33(10), 1524-36.
  85. Zobell JT, Stockmann C, Young DC, Cash J, McDowell BJ, Korgenski K, Sherwin CM, Spigarelli M, Chatfield BA, Ampofo K (2011). Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. Clin Ther, 33(11), 1844-50.
  86. Merhar SL, Schibler KR, Sherwin CM, Meinzen-Derr J, Shi J, Balmakund T, Vinks AA (2011). Pharmacokinetics of levetiracetam in neonates with seizures. J Pediatr, 159(1), 152-154.e3.
  87. Sherwin CM, Svahn S, van der Linden AJ, Medlicott NJ, Broadbent R, Reith DM (2009). Individualised Dosing of Amikacin in Neonates: a Pharmacokinetic/ Pharmacodynamic Analysis. Eur J Clin Pharmacol, 65(7), 705-13.
  88. Sherwin CM, McCaffrey F, Broadbent RS, Reith DM, Medlicott NJ (2009). Discrepancies between predicted and observed rates of intravenous gentamicin delivery for neonates. J Pharm Pharmacol, 61(4), 465-71.
  89. Sherwin CM, Kostan E, Broadbent RS, Medlicott NJ, Reith DM (2009). Evaluation of the effect of intravenous volume expanders upon the volume of distribution of gentamicin in septic neonates. Biopharm Drug Dispos, 30(5), 276-80.
  90. Sherwin C, Broadbent R, Young S, Worth J, McCaffrey F, Medlicott NJ, Reith D (2008). Utility of interleukin-12 and interleukin-10 in comparison with other cytokines and acute-phase reactants in the diagnosis of neonatal sepsis. Am J Perinatol, 25(10), 629-36.
  91. Sherwin CM, Broadbent RS, Medlicott NJ, Reith DM (2008). Individualising netilmicin dosing in neonates. Eur J Clin Pharmacol, 64(12), 1201-8.
  92. Mishra S, Storer MK, Sherwin CM, Lewis JG (2005). A simple binding assay for the direct determination of biotin in urine. Clin Chim Acta, 360(1-2), 60-6.

Review

  1. Yu T, Enioutina EY, Brunner HI, Vinks AA, Sherwin CM (2017). Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus. [Review]. Clin Pharmacokinet, 56(2), 107-125.
  2. Liu X, Yu T, Rower JE, Campbell SC, Sherwin CM, Johnson MD (2016). Optimizing the use of intravenous magnesium sulfate for acute asthma treatment in children. [Review]. Pediatr Pulmonol, 51(12), 1414-1421.
  3. Kaur I, Constance JE, Kosak KM, Spigarelli MG, Sherwin CM (2015). An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia. [Review]. Expert Opin Drug Metab Toxicol, 11(1), 53-65.
  4. Stockmann C, Constance JE, Roberts JK, Olson J, Doby EH, Ampofo K, Stiers J, Spigarelli MG, Sherwin CM (2014). Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. [Review]. Clin Pharmacokinet, 53(5), 429-54.
  5. Schoen K, Yu T, Stockmann C, Spigarelli MG, Sherwin CM (2014). Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity. [Review]. Paediatr Drugs, 16(2), 169-77.
  6. Campbell SC, Spigarelli MG, Courter J, Sherwin CM (2013). Metabolic and toxicological considerations for sepsis drug treatments. [Review]. Expert Opin Drug Metab Toxicol, 9(1), 79-89.
  7. Sherwin CM, Kiang TK, Spigarelli MG, Ensom MH (2012). Fundamentals of population pharmacokinetic modelling: validation methods. [Review]. Clin Pharmacokinet, 51(9), 573-90.
  8. Kiang TK, Sherwin CM, Spigarelli MG, Ensom MH (2012). Fundamentals of population pharmacokinetic modelling: modelling and software. [Review]. Clin Pharmacokinet, 51(8), 515-25.
  9. Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA (2011). The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. [Review]. Clin Pharmacokinet, 50(1), 1-24.

Book Chapter

  1. Krekels EHJ, Rower JE, Constance JE, Knibbe CAJ, Sherwin CM (2017). Hepatic Drug Metabolism in Pediatric Patients. In Xie, W (Eds.), Drug Metabolism in Diseases (First). Elsevier.
  2. Campbell SC, Salisbury LM, Roberts JK, Kamyar M, Fredrickson J, Costantine MM, Sherwin CM (2016). Therapeutic Drug Monitoring in Pregnancy. In W Clarke, A Dasgupta (Eds.), Clinical Challenges in Therapeutic Drug Monitoring: Special Populations, Physiological Conditions and Pharmacogenomics (First Edition, pp. 185-211). Elsevier.

Conference Proceedings

  1. Linakis MW, Liu X, Cook SF, Kumar SS, Wilkins DG, Gaedigk R, Gaedigk A, Sherwin CM, van den Anker JN (2017). UGT1A9 RS3832043 influences acetaminophen glucuronidation in neonates. American Society for Clinical Pharmacologyand Therapeutics (ASCPT), Washington, DC: Clinical Pharmacology & Therapeutics, 101(S1), S8.
  2. Balch AH, Constance J, Kumar SS, Korgenski EK, Sherbotie JR, Yu T, Sherwin CM (2017). Do physicians change tacrolimus dosing after 90 days? An EMR-based study of therapeutic drug monitoring in transplant patients. American Society for Clinical Pharmacologyand Therapeutics (ASCPT), Washington DC: Clinical Pharmacology & Therapeutics, 101(S1), S56.
  3. Liu X, Tak C, Sherwin CM, Shakib JH (2016). Population modeling of the influence of maternal influenza vaccination on infant immunity. American Association of Pharmaceutical Scientists (AAPS).
  4. Wang Y, Liu X, Constance JE, Korgenski EK, Sherwin CM (2016). Population pharmacokinetic modeling of gentamicin in children diagnosed with cancer. American Association of Pharmaceutical Scientists (AAPS).
  5. Liu X, Tak C, Sherwin CM, Shakib JH (2016). Exploring maternal-infant linked influenza antibody kinetics using a unified population model. American Conference on Pharmacometrics (ACoP), Bellevue, WA.
  6. Wang Y, Liu X, Korgenski EK, Sherwin CM (2016). Population pharmacokinetic modeling of gentamicin in pediatric patients and assessment of age influence. American Conference on Pharmacometrics (ACoP).
  7. Constance JE, Stockmann C, Linakis M, Balch A, Korgenski EK, Spraker-Perlman H, Lemons R, Sherwin CM (2016). Use of supportive care therapies among pediatric cancer patients with hematologic malignancies undergoing chemotherapy. ASCPT Pre-conference Challenges in Global Drug Development and Regulation Quantitative Translational Approaches in Oncology, San Diego, CA: Clinical Pharmacology and Therapeutics.
  8. Liu X, Lieh-lai MW, Kauffman RE, Ward RM, Sherwin CM (2016). Population pharmacokinetic modeling of morphine and Metabolites in 3-18 year-old children following surgery. American Society for Clinical Pharmacology and Therapeutics, ASCPT, San Diego, CA: Clinical Pharmacology & Therapeutics.
  9. Liu X, Balch A, Dixon CL, Costantine MM, Sherwin CM (2016). Logistic modeling of cord blood magnesium level and cerebral palsy incidence in children with maternal magnesium sulfate dosing. American Society for Clinical Pharmacology and Therapeutics, ASCPT, San Diego: Clinical Pharmacology & Therapeutics.
  10. Enioutina EY, Balch A, Wilkes J, Olsen J, Thorell E, Pavia AT, Sherwin CM (2016). IVIG use among children in freestanding children’s hospitals in the United States. American Society for Clinical Pharmacology and Therapeutics, ASCPT, San Diego: Clinical Pharmacology & Therapeutics.
  11. Linakis MW, Cook SF, Rower JE, Rollins DE, Sherwin CM, Wilkins DG (2016). Pharmacokinetics and renal clearance of beta-hydroxy-betamethylbutyrate in healthy adults. American Society for Clinical Pharmacology and Therapeutics, ASCPT, San Diego, CA: Clinical Pharmacology & Therapeutics.
  12. Abdelaziz S, Yu T, Stockmann C, Sherwin CM, Constance JE, Balch A (2016). Changes in pediatric prescribing patterns during Therapeutic drug monitoring of tacrolimus. American Society for Clinical Pharmacology and Therapeutics, ASCPT, San Diego, CA: Clinical Pharmacology & Therapeutics.
  13. Rower JE, Liu X, Yu T, Mundorff M, Sherwin CM, Johnson M (2016). Population pharmacokinetic modeling of magnesium sulfate for treatment of severe acute asthma in children in an emergency room setting. American Society for Clinical Pharmacology and Therapeutics, ASCPT, San Diego, CA: Clinical Pharmacology & Therapeutics, 99, S92-S93.
  14. Constance JE, Stockmann C, Linakis M, Balch A, Korgenski EK, Spraker-Perlman H, Lemons R, Sherwin CM (2016). Use of supportive care therapies among pediatric cancer patients with hematologic malignancies undergoing chemotherapy. American Society for Clinical Pharmacology and Therapeutics, ASCPT, San Diego, CA: Clinical Pharmacology & Therapeutics, 99, S90-S90.
  15. Yu T, Rower JE, Liu X, Balch A, Halford Z, Korgenski EK, Sherwin CM (2016). Development of a physiologically based Pharmacokinetic model of tacrolimus in adult organ transplant patients. American Society for Clinical Pharmacology and Therapeutics, ASCPT, San Diego, CA: Clinical Pharmacology & Therapeutics, 99, S71-S71.
  16. Liu X, Smits A, Yu T, Wead S, Neely AN, Kagan RJ, Healy DP, Allegaert K, Sherwin CM (2016). Amikacin pharmacokinetics in Pediatric patients with burn injuries compared to those with oncology conditions. World Conference of Pharmacometrics (WCoP), Brisbane, Australia.
  17. Liu X, Yu T, Dobson NR, McEntire BL, Ward RM, Spigarelli MG, Hunt CE, Sherwin CM (10/14/2015). Pharmacokinetic modelling of plasma and salivary caffeine circulation in infants receiving extended caffeine therapy for intermittent hypoxia treatment. American Conference on Pharmacometrics (ACoP), Crystal City, VA, Crystal City, VA: Journal of Pharmacokinetics and Pharmacodynamics, 42, S95-S96.
  18. Sinha M, Yu T, Sherwin CM, Hillard MA, Spigarelli MG, Russell SJ (6/5/2015). Comparison of the Intradermal vs. Subcutaneous Delivery of Insulin and Glucagon in T1DM. American Diabetes Association (ADA) Annual Meeting 2015, Boston, Massachusetts, Diabetes, 64, A276-A276.
  19. Yu T, Sinha M, Stockmann C, Hillard MA, Spigarelli MG, Russell SJ, Sherwin CM (2015). Population pharmacokinetics of glucagon administered by subcutaneous or intradermal route in patients with type 1 diabetes. European Association for Clinical Pharmacology and Therapeutics (EACPT), Spain, Madrid: Clinical Therapeutics, 37(8), e15.
  20. Yu T, Sinha M, Hillard MA, Sherwin CM, Russell SJ, Spigarelli MG (2015). Population Pharmacokinetics of Intradermal versus Subcutaneous Insulin Delivery in Patients with Type 1 Diabetes. American Society for Clinical Pharmacology and Therapeutics, ASCPT 2015, New Orleans, LA: Clinical Pharmacology & Therapeutics, 97, S48-S49.
  21. Stockmann C, Hersh AL, Ampofo K, Byington CL, Sherwin CM, Spigarelli MG, Pavia AT (2014). National Estimates of Pediatric Infectious Disease Hospitalizations from 1997-2009: An Analysis of the Kids’ Inpatient Database. Infectious Diseases Society of America (IDSA) Annual Meeting, Philadelphia, PA, Open Forum Infectious Diseases, 1, S4-S4.
  22. Kamyar M, Balch A, Campbell S, Robertson J, Sherwin CM, Clark EAS, Spigarelli MG, Rose N (2014). The Evaluation of Teratogen Information Service Data as it Relates to Prenatal Care. Society for Gynecologic Investigation, 61st Annual Meeting, Florence, Italy: Reproductive Sciences, 21(3), 254A-254A.
  23. Bhongsatiern J, Sherwin CM, Stockmann C, Yu T, Reith DM, Desai PB, Spigarelli MG (2014). An improved vancomycin dosing strategy in neonates using population pharmacokinetics and simulations to achieve pharmacodynamic target attainment. American Society for Clinical Pharmacology and Therapeutics, Atlanta, GA: Clinical Pharmacology & Therapeutics.
  24. Campbell SC, Stockmann C, Sherwin CM, Spigarelli MG (2014). Examination of Gentamicin and Magnesium Sulfate Drug-Drug Interactions in Neonates. American Society for Clinical Pharmacology and Therapeutics, ASCPT, Atlanta, GA: Clinical Pharmacology & Therapeutics.
  25. Balch AH, Thorell E, Constance J, Stockmann C, Korgenski K, Spigarelli MG, Sherwin CM (2014). Factors Influencing Vancomycin Dose Reduction in Neonatal and Pediatric Patients. American Society for Clinical Pharmacology and Therapeutics, ASCPT, Atlanta, GA: Clinical Pharmacology & Therapeutics, 95, S54-S55.
  26. Roberts JK, Sherwin CM, Beachy J, Ward RM, Baserga M, Spigarelli MG (2014). Pharmacokinetics of Darbepoetin Alfa in the Treatment of Hypoxic-Ischemic Encephalopathy. American Society for Clinical Pharmacology and Therapeutics, ASCPT, Atlanta, GA: Clinical Pharmacology & Therapeutics, 95, S99-S99.
  27. Constance JE, Balch A, Stockmann C, Sherwin CM, Spigarelli MG (2014). Characteristics of Pediatric Cancer Patients Receiving Vancomycin. American Society for Clinical Pharmacology and Therapeutics, ASCPT, Atlanta, GA: Clinical Pharmacology & Therapeutics, 95, S55-S55.
  28. Firth SD, Yakub SY, Sherwin CM, Korgenski K, Constance JE, Stockmann C, Balch A, Spigarelli MG (2014). Therapeutic Monitoring of Vancomycin in Children: Is There a Cost to Non-adherence of Guidelines? American Society for Clinical Pharmacology and Therapeutics, ASCPT, Atlanta, GA: Clinical Pharmacology & Therapeutics, 95, S56-S56.
  29. Yu T, Schoen K, Tak C, Clark EA, Varner MV, Spigarelli MG, Sherwin CM (2014). Population Pharmacokinetics of Caffeine and Its Metabolites in Pregnant Women. American Society for Clinical Pharmacology and Therapeutics, ASCPT, Atlanta, GA: Clinical Pharmacology & Therapeutics, 95, S94-S94.
  30. Roberts J, Beachy J, Yoder B, Ward R, Sherwin CM, Spigarelli MG, DiGeronimo R, Ohls R, Walsh W, Mayock D, Juul S, Christensen R, Baserga M (2014). DANCE (Darbe administration in newborns undergoing cooling for encephalopathy): safety and pharmacokinetic trial. Western Society for Pediatric Research (WSPR), Carmel, CA: Journal of Investigation Medicine, 62(1), 210-210.
  31. Firth SD, Yakub SY, Sherwin CM, Constance JE, Balch A, Spigarelli MG (2013). Assessment of Therapeutic Guideline Adherence for Vancomycin Use in Neonates. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 700-700.
  32. Yu T, Sherwin CM, Balch A, Ward R, Spigarelli MG (2013). Population pharmacokinetics of caffeine in neonates and infants to improve therapeutic range attainment. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 715-715.
  33. Yu T, Stockmann C, Balch A, Sherwin CM, Spigarelli MG (2013). Characteristics and Trends of Vancomycin Clinical Trials Registered in the United States from 1997-2012. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 716-716.
  34. Stockmann C, Sherwin CM, Spigarelli MG (2013). Published Therapeutic Drug Monitoring Studies: Who Is Supporting Research? 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 706-706.
  35. Stockmann C, Sherwin CM, Constance J, Campbell SC, Linakis M, Yu T, Balch A, Spigarelli MG (2013). Paediatric Under Representation in Therapeutic Drug Monitoring Studies. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 674-675.
  36. Firth SD, Yakub SY, Sherwin CM, Constance JE, Balch A, Spigarelli MG (2013). Therapeutic monitoring of Vancomycin in neonates: Is there a cost to non-adherence of guidelines? 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 681-681.
  37. Weston AS, Constance JE, Campbell SC, Stockmann C, Mihalopoulos NL, Sherwin CM, Spigarelli MG (2013). Dosing Vancomycin in Pediatric Patients with Obesity. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 688-689.
  38. Bridges ZM, Campbell SC, Thomas K, Sherwin CM, Spigarelli MG (2013). Poison Control Center Calls Regarding Exposures to Pregnant and Breastfeeding Women. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 718-719.
  39. Campbell SC, McMillin G, Sherwin CM, Spigarelli MG (2013). Thiopurine Methyltransferase Pharmacogenomic Testing: Known But Infrequently Done. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 714-715.
  40. Linakis MW, Constance J, Stockmann C, Campbell S, Sherwin CM, Spigarelli MG (2013). Frequency of Vancomycin Target Trough Attainment for Cutaneous and Invasive Staphylococcal Infections. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 697-697.
  41. Bhongsatiern J, Stockmann C, Yu T, Reith DM, Sherwin CM, Desai P, Spigarelli MG (2013). An External Evaluation of Vancomycin Pharmacokinetics Among Septic Neonates. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 664-664.
  42. Constance JE, Balch A, Campbell SC, Stockmann C, Sherwin CM, Spigarelli MG (2013). Frequency of achieving the therapeutic range with vancomycin in infants, children and adolescents. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 674-647.
  43. Green A, Campbell SC, Thomas K, Sherwin CM, Spigarelli MG (2013). Medication Exposures during Pregnancy and Breastfeeding. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 704-704.
  44. Stockmann C, Sherwin CM, Zobell JT, Lubsch L, Young DC, Olson J, Noyes BE, Ampofo K, Spigarelli MG (2013). Population Pharmacokinetics of Vancomycin Used in the Treatment of Pediatric Cystic Fibrosis Pulmonary Exacerbations. American Conference on Pharmacometrics (ACoP), Fort Lauderdale, FL: Journal of Pharmacokinetics and Pharmacodynamics, 40, S132-S132.
  45. Sherwin CM, Stockmann C, Zobell JT, McCrory B, Wisdom M, Young DC, Olson J, Ampofo K, Spigarelli MG (2013). A Pharmacokinetic Evaluation of Tobramycin Administered One, Two, and Three Times Daily to Children with Cystic Fibrosis. American Conference on Pharmacometrics (ACoP), Fort Lauderdale, FL: Journal of Pharmacokinetics and Pharmacodynamics, 40, S131-S131.
  46. Bhongsatiern J, C Stockmann C, Yu T, Spigarelli MG, Sherwin CM (2013). Neonatal population pharmacokinetics and pharmacodynamics modeling of vancomycin to simulate target exposure attainment. American Society for Clinical Pharmacology and Therapeutics, ASCPT, Indianapolis, Indiana: Clinical Pharmacology & Therapeutics.
  47. Constance JE, Campbell SC, Linakis MW, Sherwin CM, Spigarelli MG (2013). Dosing of vancomycin in neonates: on target for the therapeutic range? American Society for Clinical Pharmacology and Therapeutics, ASCPT, Indianapolis, Indiana: Clinical Pharmacology & Therapeutics.
  48. Fredrickson J, Balch A, Campbell SC, Sherwin CM, Clark EA, Spigarelli MG (2013). Intrapartum use of magnesium sulfate and the relationship between maternal and neonatal magnesium blood levels. American Society for Clinical Pharmacology and Therapeutics, ASCPT, Indianapolis, Indiana: Clinical Pharmacology & Therapeutics, 93, S48-S49.
  49. Campbell SC, Sherwin CM, Balch AH, Clark EA, Spigarelli MG (2013). Examination of intrapartum use of magnesium sulfate and potential drug-drug interactions. American Society for Clinical Pharmacology and Therapeutics, ASCPT, Indianapolis, Indiana: Clinical Pharmacology & Therapeutics, 93, S20-S20.
  50. Yakub SY, Campbell SC, Sherwin CM, Constance J, Balch A, Spigarelli MG (2013). Trends of use of vancomycin in neonates. American Society for Clinical Pharmacology and Therapeutics, ASCPT, Indianapolis, Indiana: Clinical Pharmacology & Therapeutics, 93, S49-S50.
  51. De Cock RFW, Allegaert K, Sherwin CM, de Hoog M, van den Anker JN, Danhof M, Knibbe CAJ (2012). Maturation of glomerular filtration rate in preterm and term neonates as reflected by clearance of amikacin, netilmicin and vancomycin. American Society for Clinical Pharmacology and Therapeutics, Baltimore, MA: Clinical Pharmacology & Therapeutics, 91(Suppl. 1), S28.
  52. Jones BL, Sherwin CM, Neville KA, Spigarelli MG, Kearns GL, Leeder JS (2012). Evidence of distinct histamine pharmacodynamic phenotypes in children. American Society for Clinical Pharmacology and Therapeutics (ASCPT), Baltimore, MA, Clinical Pharmacology & Therapeutics, Supplement 1. (March 2012), 91, S28.
  53. Sagcal-Gironella AC, Sherwin CM, Tirona RG, Rieder MJ, Brunner HI, Vinks AA (2011). Open-label, single dose pharmacokinetic study of prednisolone at steady state in young patients with SLE on prednisone therapy. European Association for Clinical Pharmacology and Therapeutics (EACPT), Budapest, Hungary: Clinical Therapeutics, 33(10), 1524.
  54. De Cock RFW, Allegaert K, de Hoog M, Sherwin CM, Danhof M, Knibbe CAJ (2011). Predicting glomerular filtration rate using clearance of amikacin in neonates–Model Evaluation. British Pharmacological Society, British Journal of Clinical Pharmacology, 72(5), 846-847.
  55. Zobell JT, Stockmann C, Young DC, Cash J, Sherwin CM, Spigarelli M, Chatfield BA, Ampofo K (2011). Population pharmacokinetic (PK) and pharmacodynamic (PD) modeling of ticarcillin-clavulanate in pediatric CF patients. North American Cystic Fibrosis (NACF) Conference, Anaheim, CA: Pediatr Pulmon, Suppl 34, 277.
  56. Saldana SN, Sherwin CM, Bies RR, Kuijvenhovem M, Aman M, Vinks AA (2011). Population Pharmacokinetics of Risperidone Using Sparse and D-Optimal Sampling in Children and Adolescents. American Society for Clinical Pharmacology and Therapeutics, Dallas, TX: Clinical Pharmacology & Therapeutics, 89, S56-S57.
  57. Sherwin CM, Sagcal-Gironella AC, Fukuda T, Brunner HI, Vinks AA (2010). Development of a population pharmacokinetic model with enterohepatic recirculation for mycophenolic acid in patients with childhood systemic lupus erythmatosus (cSLE). American Society for Clinical Pharmacology and Therapeutics (ASCPT), Atlanta, GA, Atlanta, GA: Clinical Pharmacology & Therapeutics, 87, S61-S61.
  58. Medlicott NJ, Sherwin CM, Broadbent R, McCaffrey F, Reith DM (2008). Intravenous Infusions of Gentamicin in Neonate Patients - Effects of Infusion Variables on Drug Administration Rates. Royal Pharmaceutical Society Conference, Manchester, UK: Journal of Pharmacy and Pharmacology, 60(26 Suppl.), A11.
  59. Sherwin CM, McCaffrey F, Broadbent RS, Reith DM and Medlicott NJ (2008). Investigation Into the Intravenous Delivery of Aminoglycoside Antibiotics to Extremely Premature Neonates. 11th Biannual European Society for Developmental Perinatal and Pediatric Pharmacology Congress; Rotterdam, The Netherlands.

Editorial

  1. Ward RM, Sherwin CM (2016). Newborns still lack drug data to guide therapy. Br J Clin Pharmacol, 82(6), 1410-1411.
  2. Allegaert K, Sherwin CM (2016). Neonates and medicines: a roadmap to further improve neonatal pharmaceutical care. Eur J Pediatr.

Letter

  1. Stockmann C, Sherwin CM, Knackstedt ED, Hersh AL, Pavia AT, Spigarelli MG (2016). Therapeutic Drug Monitoring of Ganciclovir Treatment for Cytomegalovirus Infections Among Immunocompromised Children.LID - piw008 [pii] [Letter to the editor]. J Pediatric Infect Dis Soc.
  2. Stockmann C, Ross JS, Sherwin CM, Reilly CA, McDowell B, Fassl B, Nkoy F, Maloney CG, Spigarelli MG (2014). Rate of asthma trial outcomes reporting on ClinicalTrials.gov and in the published literature [Letter to the editor]. J Allergy Clin Immunol, 134(6), 1443-6.
  3. Allegaert K, Sherwin CM (2010). Amikacin in neonates: dosing recommendations should be based on both pharmacokinetics and dynamics [Letter to the editor]. Singapore Med J, 51(1), 88-9.
  4. Sherwin CM, Broadbent R, Medlicott NJ, Reith DM (2009). Individualized Dosing of Amikacin in Neonates [Letter to the editor]. Eur J Clin Pharmacol, 65(12), 1267-1268.
  5. Sherwin CM, Svahn S, Broadbent RS, Van Der Linden A, Medlicott NJ, Reith DM (2008). Netilmicin withdrawal: impact on neonates [Letter to the editor]. N Z Med J, 121(1284), 95-7.

Abstract

  1. Rattler TB Constance J, Sherwin CM (5/30/2016). Polypharmacy Among Hospitalized Pediatric Patients with Type 1 Diabetes Mellitus [Abstract]. Society for Advancement of Chicanos/Hispanics and Native Americans in Science (SACNAS).
  2. Molina K, Rower J, Stockmann C, Sherwin CM (2016). Predicting Tacrolimus Concentrations in Heart Transplant Recipients Using Population Pharmacokinetic Models [Abstract]. American Heart Association, New Orleans, LA.
  3. Caston R, Constance JE, Balch A, Korgenski EK, Sherwin CM (2016). Vancomycin-associated nephrotoxicity among Pediatric patients with hematologic malignancy [Abstract]. American College of Clinical Pharmacology (ACCP) Annual Meeting.
  4. Balch A, Yu T, Constance JE, Sherbotie J, Rower J, Korgenski EK, Sherwin CM (2016). Is Generic Tacrolimus Bioequivalent In Patients? [Abstract]. American College of Clinical Pharmacology (ACCP) Annual Meeting.
  5. Ford TA, Constance JE, Sherwin CM (2016). Type 1 Diabetes And The Risk Of Kidney Dysfunction Among Children Receiving Intravenous Antibiotics [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting 2016, Baltimore, MA.
  6. Constance JE, Rower J, Stockmann C, Balch A, Sherwin CM, Spigarelli MG (10/29/2015). IV anti-infective use in pediatric patients with cancer [Abstract]. Translating Cancer Epidemiology, Huntsman Cancer Institute, Salt Lake City, UT.
  7. Constance JE, Linakis MW, Stockmann C, Roberts JK, Sherwin CM, Spigarelli MG (10/29/2015). Inpatient polypharmacy among children with leukemia or lymphoma receiving IV antibiotic therapy within the first year from diagnosis [Abstract]. Translating Cancer Epidemiology, Huntsman Cancer Institute, Salt Lake City, UT.
  8. Liu X, Yu T, Balch AH, Sherbotie J, Korgenski EK, Spigarelli MG, Sherwin CM (10/26/2015). Population Pharmacokinetics of Tacrolimus in Pediatric Patients with Kidney Transplant [Abstract]. American Association of Pharmaceutical Scientists (AAPS), 2015, Orlando, FL.
  9. Yu T, Liu X, Balch AH, Molina KM, Constance JE, Prevedel JA, Korgenski EK, Spigarelli MG, Sherwin CM (10/26/2015). Population pharmacokinetics of tacrolimus in pediatric heart transplant patients [Abstract]. American Association of Pharmaceutical Scientists (AAPS), 2015, Orlando, FL.
  10. Linakis MW, Sherwin CM, Roberts JK, Spigarelli MG, Wilkins DG (10/26/2015). Population pharmacokinetics of nicotine delivered from a transdermal matrix patch [Abstract]. American Association of Pharmaceutical Scientists (AAPS), 2015, Orlando, FL.
  11. Balch A, Green T, Hansen C, Sherwin CM (8/10/2015). Practical Issues in Calculating Sample Size for Ordinal Data with Repeated Measures [Abstract]. Joint Statistical Meeting (JSM) 2015, Seattle, WA.
  12. Constance JE, Ward RM, Sherwin CM, Korgenski K, Spigarelli MG (9/26/2015). Nonsteroidal anti-inflammatory drug-associated nephrotoxicity among neonates diagnosed with patent ductus arteriosus [Abstract]. American College of Clinical Pharmacology (ACCP), 2015, San Francisco, CA.
  13. Balch AH, Constance JE, Sherwin CM, Spigarelli MG (9/26/2015). A Retrospective Study of Kidney Injury vs Vancomycin Use by Age [Abstract]. American College of Clinical Pharmacology (ACCP), 2015, San Francisco, CA.
  14. Constance JE, Linakis MW, Balch AH, Sherwin CM, Spigarelli MG (10/14/2015). Inpatient polypharmacy among children with leukemia or lymphoma receiving IV antibiotic therapy within the first year from diagnosis [Abstract]. IATDMCT Congress 2015, Rotterdam, The Netherlands.
  15. Schiffman JD, Kirchhoff AC, Spigarelli MG, Kaul S, Smits-Seemann R, Sherwin CM, Constance JE, Brenna Eldridge B, Fluchel M, Christenson CP, Garfield K, Mason CC, Korgenski EK Knackstedt ED, Blaschke A, Raetz EA, Lemons RS, Clark EB (5/29/2015). Building a comprehensive, value-based resource for childhood cancer in Utah [Abstract]. American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, Illinois, 2015.
  16. Stockmann C, Hersh AL, Sherwin CM, Spigarelli MG, Frymoyer A (2015). Targeting Vancomycin AUC in Neonates - A Model Based Bayesian Approach for Personalized Therapeutic Drug Monitoring [Abstract]. American Society for Clinical Pharmacology and Therapeutics, ASCPT 2015.
  17. Constance JE, Balch AH, Enioutina EY, Stockmann C, Linakis M, Sherwin CM, Spigarelli MG (2015). Polypharmacy among hospitalized pediatric cancer patients [Abstract]. American Society for Clinical Pharmacology and Therapeutics, ASCPT 2015.
  18. Bhongsatiern J, Stockmann C, Yu T, Moorthy G, Constance JE, Spigarelli MG, Desai PB, Sherwin CM (2015). Renal function descriptors in neonates: Which creatinine-based equation best describes vancomycin clearance? [Abstract]. American Society for Clinical Pharmacology and Therapeutics, ASCPT 2015.
  19. Balch AH, Constance JE, Sherwin CM, Spigarelli MG (2015). The Effect of tyrosine kinase inhibitors on pediatric growth [Abstract]. American Society for Clinical Pharmacology and Therapeutics, ASCPT 2015.
  20. Enioutina EY, Constance JE, Balch AH, Sherwin CM, Spigarelli MG (2015). Vaccination patterns among pediatric cancer patients treated with vancomycin [Abstract]. American Society for Clinical Pharmacology and Therapeutics, ASCPT 2015.
  21. Prevedel JA, Constance JE, Sherwin CM, Spigarelli MG (2015). Patterns of Tacrolimus Use in Pediatric Heart Transplant Recipient [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting, 2015, San Diego, CA.
  22. Clements N, Constance JE, Yu T, Campbell SC, Linakis M, Sherwin CM, Spigarelli MG (2014). Therapeutic drug monitoring and target vancomycin attainment among pediatric patients undergoing hemodialysis [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Diego, CA.
  23. Yu T, Stockmann C, Constance JE, Korgenski EK, Spigarelli MG, Sherwin CM (2014). Population Pharmacokinetics and Dosing Regimen Optimization of Intravenous Vancomycin in Infants [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Diego, CA.
  24. Constance JE, Sherwin CM, Korgenski EK Spigarelli MG (2014). Intravenous meropenem use among pediatric patients with and without cancer [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Diego, CA.
  25. Sneddon JR, Campbell SC, Balch AH, Sherwin CM, Spigarelli MG (2014). Trends of KRAS Pharmacogenomic Testing for Cetuximab and Panitumumab [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Diego, CA.
  26. Linakis MW, Stockmann C, Campbell SC, Williams RV, Burch PT, Lambert LM, Sherwin CM, Reilly CA, Spigarelli MG (2014). A Novel Sensitive and Specific Liquid Chromatography-Tandem Mass Spectrometry (LC-MS-MS) Method for the Quantification of Oxandrolone in Human Plasma [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Diego, CA.
  27. Campbell SC, Johnson-Davis KL, Linakis MW, McMillin GA, Sherwin CM, Spigarelli MG (2014). Evaluating the Relationship of Age and Thiopurine Metabolites in Pediatrics [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Diego, CA.
  28. Roberts JK, Ward RM, Beachy J, Baserga M, Spigarelli MG, Sherwin CM (2014). Population pharmacokinetics of darbepoetin alfa for the treatment of neonatal hypoxic-ischemic encephalopathy [Abstract]. American Conference on Pharmacometrics (ACoP), Las Vegas, NV.
  29. Bhongsatiern J, Sherwin CM, Yu T, Stockmann C, Allegaert K, Knibbe CAJ, Reith DM, Desai PB, Spigarelli MG (2014). Development of Vancomycin Dosing Recommendations in Preterm and Term Neonates using Population Pharmacokinetic Modeling and Simulation [Abstract]. American Conference on Pharmacometrics (ACoP), Las Vegas, NV.
  30. Stockmann C, Sherwin CM, Spigarelli MG (2014). zscore – An R Package for Deriving Weight and Height for Age Z Scores and Exact Percentiles from Birth to 20 Years of Age [Abstract]. American Conference on Pharmacometrics (ACoP), Las Vegas, NV.
  31. Cook SF, Sherwin CM, Williams EF, Roberts JK, King AD, Deutsch N, Samiee-Zafarghandy S, Mankala S, Wilkins DG, van den Anker JN (2014). Population pharmacokinetics of intravenous acetaminophen in preterm and term neonates [Abstract]. American Conference on Pharmacometrics (ACoP), Las Vegas, NV.
  32. Yu T, Campbell SC, Stockmann C, Clark EAS, Varner MW, Spigarelli MG, Sherwin CM (2014). Pharmacokinetic Changes of Caffeine during Pregnancy and Simulation of Pregnant Population [Abstract]. American Conference on Pharmacometrics (ACoP), Las Vegas, NV.
  33. Baserga M, Beachy J, Yoder BA, Ward RM, Roberts JK, Sherwin CM, Spigarelli MG, DiGeronimo R, Ohls R, Walsh W, Mayock D, Juul SE, Christensen R (2014). DANCE (Darbe Administration in Newborns Undergoing Cooling for Encephalopathy: Safety and Pharmacokinetic Trial. American Academy of Pediatrics [Abstract]. American Academy of Pediatrics (AAP) National Conference and Exhibition, San Diego, CA.
  34. Balch AH, Constance JE, Sherwin CM, Spigarelli MG (2014). Pediatric Cancer Patients Receiving Gentamicin and Vancomycin Receive Higher Doses and More Combination Therapy [Abstract]. American Academy of Pediatrics (AAP) National Conference and Exhibition, San Diego, CA.
  35. Linakis MW, Campbell SC, Stockmann C, Johnson-Davis KL, McMillin GA, Balch AH, Sherwin CM, Spigarelli MG (2014). Frequency of Thiopurine Metabolite Tests with Clinically-Important Results Requiring Modifications to Therapy [Abstract]. American Academy of Pediatrics (AAP) National Conference and Exhibition, San Diego, CA.
  36. Han H, Constance JE, Sherwin CM, Korgenski EK, Spigarelli MG (2014). Evaluation of disparities in achieving therapeutic recommendations among pediatric patients receiving gentamicin [Abstract]. American College of Clinical Pharmacology (ACCP) Annual Meeting.
  37. Linakis MW, Campbell SC, Stockmann C, Johnson-Davis KL, McMillin GA, Sherwin CM, Spigarelli MG (2014). Regional Differences in Thiopurine Methyltransferase Activity [Abstract]. American College of Clinical Pharmacology (ACCP) Annual Meeting.
  38. Constance JE, Balch AH, Sherwin CM, Spigarelli MG (2014). Patterns of Gentamicin Use Among Pediatric Cancer Patients [Abstract]. American College of Clinical Pharmacology (ACCP) Annual Meeting.
  39. De Cock RFW, Allegaert K, Brussee J, Sherwin CM, Mulla H, de Hoog M, van den Anker JN, Danhof M, Knibbe CAJ (2014). Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration [Abstract]. PAGE 23. Population Approach Group in Europe. Abstr 3167. www.page-meeting.org/?abstract=3167], Alicante, Spain.
  40. Stockmann C, Hersh AL, Pavia AT, Byington CL, Blaschke AJ, Sherwin CM, Spigarelli MG, Ampofo K (2014). National Trends in Pediatric Pyogenic Arthritis and Osteomyelitis, 1997 – 2009 [Abstract]. Pediatric Academic Societies & Asian Society for Pediatric Research Joint Meeting, Vancouver, Canada.
  41. Campbell SC, Johnson-Davis K, McMillin GA, Sherwin CM, Spigarelli MG (2014). Trends of Pediatric and Adolescent TPMT Pharmacogenomic Testing [Abstract]. Pediatric Academic Societies & Asian Society for Pediatric Research Joint Meeting, Vancouver, Canada.
  42. Campbell SC, Johnson-Davis K, Linakis MW, Roberts JK, McMillin GA, Sherwin CM, Spigarelli MG (2014). Evaluating the Relationship of Age and Thiopurine Methyltransferase Activity [Abstract]. Pediatric Academic Societies & Asian Society for Pediatric Research Joint Meeting, Vancouver, Canada.
  43. Yu T, Balch AH, Spigarelli MG, Sherwin CM (2014). Population Pharmacokinetics/Pharmacodynamics of Intravenous Vancomycin in Adolescent Patients [Abstract]. Pediatric Academic Societies & Asian Society for Pediatric Research Joint Meeting, Vancouver, Canada.
  44. Roberts JK, Sherwin CM, Beachy J, Ward RM, Baserga M, Spigarelli MG (2014). Pharmacokinetics of Darbepoetin Alfa in the Treatment of Hypoxic-Ischemic Encephalopathy [Abstract]. Pediatric Pharmacogenomics and Personalized Medicine Conference, Kansas City, MO, Encore.
  45. Constance JE, Campbell SC, Stockmann C, Balch AH, Korgenski EK, Sherwin CM, Spigarelli MG (2014). Incidence of acute kidney injury among vancomycin-treated children with hematologic malignancies [Abstract]. Pediatric Pharmacogenomics and Personalized Medicine Conference, Kansas City, MO.
  46. Doll E, Wilkes J, Sherwin CM, Srivastava R, Faix R, Spigarelli MG, Clark EAS, Bonkowsky J (2013). Neonatal Magnesium Levels Correlate with Improved Neurological Outcomes in Premature Infants [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting, Washington DC.
  47. Bhongsatiern J, Sherwin CM, Stockmann C, Yu T, Reith DM, Desai PB Spigarelli MG (2013). Use of Monte Carlo Simulation to Evaluate Vancomycin Dosing Regimens in Neonates [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Antonio, TX.
  48. Yu T, Stockmann C, Sherwin CM, Olson J, Healy D, Spigarelli MG (2013). Determination of an Optimal Amikacin Dosing Regimen for Pediatric Burn Patients [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Antonio, TX.
  49. Constance JE, Balch A, Campbell SC, Stockmann C, Sherwin CM, Spigarelli MG (2013). Nephrotoxicity associated with vancomycin use in a pediatric population [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Antonio, TX.
  50. Campbell SC, Linakis MW, Tak CR, McMillin G, Sherwin CM, Spigarelli MG (2013). Clinical Utilization of Pharmacogenomic Testing: What is it for Drugs with Strong Recommendations? [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Antonio, TX.
  51. Firth SD, Yakub SY, Sherwin CM, Korgenski K, Constance JE, Stockmann C, Balch A, Spigarelli MG (2013). Assessment of Guideline Adherence for Pediatric Vancomycin Use [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Antonio, TX.
  52. Firth SD, Yakub SY, Sherwin CM, Korgenski K, Constance JE, Stockmann C, Balch A, Spigarelli MG (2013). Therapeutic Monitoring of Vancomycin in Children: Is There a Cost to Non-adherence of Guidelines? [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Antonio, TX.
  53. Yu T, Sherwin CM, Stockmann C, Spigarelli MG (2013). Evolution of Vancomycin Clinical Trials and Development of New Antibiotic Therapies for Resistant Gram-Positive Bacterial Infections in the United States from 1999 to 2012 [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Antonio, TX.
  54. Schoen K, Constance J, Sherwin CM, Ward R, Spigarelli MG (2013). Determination of Vancomycin Induced Nephrotoxicity in Neonates with Patent Ductus Arteriosus [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Antonio, TX.
  55. Sherwin CM, Jones B, Leeder JS, Neville KA, Kearns GL, Spigarelli MG (2013). Dense Data - Methods to Handle Massive Data Sets without Compromise [Abstract]. PAGE 22. Population Approach Group in Europe. Abstr 2942. www.page-meeting.org/?abstract=2942. Glasgow, Scotland.
  56. Spigarelli MG, Healy D, Buterbaugh W, Gottschlich MM, Kagan R, Sherwin CM (2013). Rapid Repeat Dosing of Zolpidem - Apparent Kinetic Change Between Doses [Abstract]. PAGE 22. Population Approach Group in Europe. Abstr 2943. www.page-meeting.org/?abstract=2943, Glasgow, Scotland.
  57. Sherwin CM, Stockmann C, Healy D, Buterbaugh W, Gottschlich MM, Spigarelli MG, Kagan R (2013). Population Pharmacokinetics of Zolpidem among Children with Severe Burn Injuries [Abstract]. In: 14th Biannual Congress of the European Society for Developmental Perinatal and Pediatric Pharmacology (ESDPPP). Salzburg, Austria, 04.-07.06.2013. Düsseldorf: German Medical Science GMS Publishing House; 2013.DocFP13.DOI: 10.3205/13esdppp13, URN: urn:nbn:de:0183-13esdppp133.
  58. Sherwin CM, Constance JE, Spigarelli M G (2013). Comparison of Serum Vancomycin Concentrations in a Paediatric Population pre- and post- 2009 IDSA Guideline Recommendations [Abstract]. In: 14th Biannual Congress of the European Society for Developmental Perinataland Pediatric Pharmacology (ESDPPP). Salzburg, Austria, 04.-07.06.2013. Düsseldorf: German Medical Science GMS Publishing House;2013. DocPP55.DOI: 10.3205/13esdppp82, URN: urn:nbn:de:0183-13esdppp823.
  59. Sherwin CM, Wead S, Stockmann CR, Healy D, Spigarelli MG, Neely, A (2013). Amikacin Population Pharmacokinetics Associated with Pediatric Burn Patients [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting, Washington DC.
  60. Campbell SC, McMillin GA, Sherwin CM, Spigarelli, MG (2013). Thiopurine Methyltransferase Pharmacogenomic Test Utilication in Pediatrics [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting, Washington DC.
  61. Yakub SY, Campbell SC, Sherwin CM, Constance J, Balch A, Spigarelli MG (2013). Prolonged Vancomycin Use in a Pediatric Population [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting Washington DC.
  62. Linakis M, Constance J, Bailey S, Stockmann C, Campbell SC, Balch A, Sherwin CM, Spigarelli MG (2013). Role of MRSA and Coagulase-Negative Staphylococcus Bacteremia in the Increasing Use of Vancomycin.http://www.healio.com/pediatrics/emerging-diseases/news/online/%7B323e9862-f13f-4310-bf57-13da6a267ab1%7D/vancomycin-use-increased-despite-modest-increase-in-mrsa-and-coagulase-negative-staphylococcus [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting, Washington DC.
  63. Constance J, Durbano D, Campbell SC, Sherwin CM, Balch A, Spigarelli MG (2013). Nephrotoxicity Associated with Vancomycin Use in a Neonatal Population [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting, Washington DC.
  64. Balch A, Stockmann C, Constance J, Yu T, Campbell SC, Sherwin CM, Spigarelli MG (2013). Therapeutic Monitoring of Vancomycin Concentrations and Healthcare Provider Response to High and Low Troughs [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting, Washington DC.
  65. Stockmann C, Sherwin CM, Campbell SC, Linakis M, Constance J, Balch A, Spigarelli MG (2013). Characteristics of Maternal-Fetal Pharmacology Studies Registered in the United States through ClinicalTrials.gov [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting, Washington DC.
  66. Green AA, Campbell SC, Sherwin CM, McMillin GA, Spigarelli MG (2013). Pharmacogenomic Testing Trends in Pediatric Patients [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting, Washington DC.
  67. Campbell SC, McMillin GA, Sherwin CM, Spigarelli MG (2013). Pharmacogenomic Testing Trends in Adolescents [Abstract]. Pediatric Pharmacogenomics and Personalized Medicine Conference, Kansa City, MO.
  68. Campbell SC, Sherwin CM, McMillin GA, Spigarelli M (2012). Understanding the Use and Trends of Pharmacogenomic Testing [Abstract]. American Association of Pharmaceutical Scientists (AAPS), Chicago, IL.
  69. Burch P, Minich LL, Spigarelli M, Lambert L, Sherwin CM, Williams RV (2012). Use of Oxandrolone to Promote Growth In Neonates with Complex Congenital Heart Disease: An Open-Label Pilot Trial [Abstract]. American Academy of Pediatrics (AAP) National Conference and Exhibition.
  70. Dowse B, Campbell S, Sherwin CM, Spigarelli M (2012). Trends in use and monitoring of vancomyin in pediatric patients [Abstract]. American College of Clinical Pharmacology (ACCP) Annual Meeting.